Literature DB >> 25704864

Low testosterone is associated with poor health status in men with human immunodeficiency virus infection: a retrospective study.

V Rochira1, C Diazzi, D Santi, G Brigante, A Ansaloni, M C Decaroli, S De Vincentis, C Stentarelli, S Zona, G Guaraldi.   

Abstract

Men with human immunodeficiency virus (HIV) infection are often hypogonadal and develop several HIV-associated non-acquired immunodeficiency syndrome (AIDS) (HANA) conditions that impair overall health status. No studies explored the relationship between health status and serum testosterone (T) in HIV-infected men. This study aims to investigate the association between total serum T and HANA, multimorbidity, and frailty in a large cohort of 1359 HIV-infected men and to explore the relationship between patients' overall health status and serum T. Among biochemical and hormonal measurement performed the main are serum total T, free triiodothyronine (fT3), and luteinizing hormone. Other outcome measurements include anthropometry, assessment of comorbidities and disabilities, overall health status defined as the number of HANA and by the 38-item multimorbidity frailty index, anthropometry, and bone mineral density. The cumulative relative risk of comorbidities is increased in HIV-infected men with hypogonadism (p < 0.001) and hypogonadism is associated with several comorbidities. The prevalence of hypogonadism increases progressively with the increase of the number of comorbidities. Frailty index is inversely related to serum total T (age-adjusted r = 0.298, r(2) = 0.089, p < 0.0001). Serum fT3 levels are significantly lower in hypogonadal than eugonadal men (p = 0.022). This suggests that low serum T could be considered a sensitive marker of frailty and poor health status and that the latter might induce hypogonadism. The more HIV-infected men are frail the more they are hypogonadal. This suggests that hypogonadism might be a naturally occurring condition in unhealthy HIV-infected men and raises concern about the safety of T treatment. In conclusion, low serum T is associated with multimorbidity, HANA, and frailty in HIV-infected men and this association seems to be bidirectional. Given the wide attitude to offer T treatment to HIV-infected men, caution is needed when prescribing T to HIV-infected male patients, especially if the patient is unhealthy or frail.
© 2015 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  comorbidities; frailty; highly active antiretroviral therapy; human immunodeficiency virus infection; male hypogonadism; poor health status; serum testosterone

Mesh:

Substances:

Year:  2015        PMID: 25704864     DOI: 10.1111/andr.310

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  16 in total

Review 1.  Endocrinological aspects of HIV infection.

Authors:  F S Mirza; P Luthra; L Chirch
Journal:  J Endocrinol Invest       Date:  2018-01-08       Impact factor: 4.256

2.  Clinical and biological markers of premature aging after autologous SCT in childhood cancer.

Authors:  A Vatanen; M Hou; T Huang; O Söder; T Jahnukainen; M Kurimo; T H Ojala; T Sarkola; M Turanlahti; U M Saarinen-Pihkala; K Jahnukainen
Journal:  Bone Marrow Transplant       Date:  2017-01-09       Impact factor: 5.483

Review 3.  Aging and sex hormones in males.

Authors:  Maria Chiara Decaroli; Vincenzo Rochira
Journal:  Virulence       Date:  2016-11-10       Impact factor: 5.882

4.  Pituitary growth hormone (GH) secretion is partially rescued in HIV-infected patients with GH deficiency (GHD) compared to hypopituitary patients.

Authors:  Chiara Diazzi; Giulia Brigante; Giulia Ferrannini; Anna Ansaloni; Lucia Zirilli; Maria Cristina De Santis; Stefano Zona; Giovanni Guaraldi; Vincenzo Rochira
Journal:  Endocrine       Date:  2016-10-11       Impact factor: 3.633

5.  Inflammation, Immune Activation, Immunosenescence, and Hormonal Biomarkers in the Frailty-Related Phenotype of Men With or at Risk for HIV Infection.

Authors:  Kristine M Erlandson; Derek K Ng; Lisa P Jacobson; Joseph B Margolick; Adrian S Dobs; Frank J Palella; Jordan E Lake; Hanhvy Bui; Lawrence Kingsley; Todd T Brown
Journal:  J Infect Dis       Date:  2017-01-15       Impact factor: 5.226

6.  Administration of an activin receptor IIB ligand trap protects male juvenile rhesus macaques from simian immunodeficiency virus-associated bone loss.

Authors:  Wen Guo; Karol M Pencina; Karyn O'Connell; Monty Montano; Liming Peng; Susan Westmoreland; Julie Glowacki; Shalender Bhasin
Journal:  Bone       Date:  2017-01-26       Impact factor: 4.398

Review 7.  HIV and the Pituitary Gland: Clinical and Biochemical Presentations.

Authors:  Joyce Youssef; Rohan Sadera; Dushyant Mital; Mohamed H Ahmed
Journal:  J Lab Physicians       Date:  2021-05-19

Review 8.  Frailty and HIV: Moving from Characterization to Intervention.

Authors:  Kristine M Erlandson; Damani A Piggott
Journal:  Curr HIV/AIDS Rep       Date:  2021-04-05       Impact factor: 5.495

Review 9.  Hypogonadism in the HIV-Infected Man.

Authors:  Nicholas Wong; Miles Levy; Iain Stephenson
Journal:  Curr Treat Options Infect Dis       Date:  2017-02-14

10.  Hypogonadotropic hypogonadism in human immunodeficiency virus-infected men: uncommonly low testosterone levels.

Authors:  Ana Coelho Gomes; José Maria Aragüés; Sílvia Guerra; Joana Fernandes; Mário Rui Mascarenhas
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2017-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.